| Anisoylated plasminogen streptokinase activator complex versus placebo. A preliminary multicentre study of safety and early mortality in acute myocardial infarction. | |
| | |
MedLine Citation:
|
PMID: 3315604 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
90 patients were enrolled into this preliminary multicentre study of the efficacy and safety of 30 units intravenous anisoylated plasminogen streptokinase activator complex (APSAC) compared with placebo in patients with acute myocardial infarction. 45 patients received APSAC and 45 placebo; the groups were similar for age, weight and site of infarction. There were significantly more women treated with APSAC (p less than 0.02). The mean time to treatment was 3.3 hours after symptoms of myocardial infarction for APSAC and 3 hours for placebo. The 30-day mortality was 7 patients in the placebo group and 1 in the APSAC group (p = 0.058). Adverse events were generally minor and were of similar overall frequency in both groups. There were more haemorrhagic events with APSAC, from which all patients recovered, and more cardiovascular events with placebo including 2 deaths from cardiogenic shock. APSAC showed a trend towards a reduction in 30-day mortality. Experience from this study has led to the initiation of the APSAC in myocardial infarction multicentre mortality study (AIMS). |
| | |
Authors:
|
D G Julian; L S Borthwick; D Reid; K P Jennings; R J Wainwright; J C Rodger; D Wood; W S Phillips |
Related Documents
:
|
8391984 - Preserved oxidative activity and chemotaxis of circulating neutrophils in patients with... 17916934 - Increases of calcium, phosphorus, and magnesium in both the right and left fibrous trig... 6377564 - Acylated streptokinase--plasminogen complex in patients with acute myocardial infarction. 6488304 - Intravenous versus intracoronary streptokinase for acute transmural myocardial infarction. 2347124 - Unrecognized left ventricular dysfunction in an apparently healthy cocaine abuse popula... 22121044 - The prognostic role of mitral regurgitation after primary percutaneous coronary interve... |
Publication Detail:
|
Type: Clinical Trial; Controlled Clinical Trial; Journal Article |
Journal Detail:
|
Title: Drugs Volume: 33 Suppl 3 ISSN: 0012-6667 ISO Abbreviation: Drugs Publication Date: 1987 |
Date Detail:
|
Created Date: 1988-01-07 Completed Date: 1988-01-07 Revised Date: 2007-11-15 |
Medline Journal Info:
|
Nlm Unique ID: 7600076 Medline TA: Drugs Country: NEW ZEALAND |
Other Details:
|
Languages: eng Pagination: 261-7 Citation Subset: IM |
Affiliation:
|
1 Freeman Hospital, Newcastle upon Tyne. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Anistreplase Blood Pressure / drug effects Clinical Trials as Topic Female Fibrinolytic Agents / adverse effects, therapeutic use* Hemorrhage / chemically induced Humans Injections, Intravenous Male Middle Aged Myocardial Infarction / drug therapy*, mortality Plasminogen / adverse effects, therapeutic use* Random Allocation Streptokinase / adverse effects, therapeutic use* |
| Chemical | |
Reg. No./Substance:
|
0/Fibrinolytic Agents; 81669-57-0/Anistreplase; 9001-91-6/Plasminogen; EC 3.4.-/Streptokinase |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Analysis of coagulation and fibrinolysis after intravenous anisoylated plasminogen streptokinase act...
Next Document: Biological study of intravenous anisoylated plasminogen streptokinase activator complex in acute myo...